Note: Merck KGaA of Germany is unrelated to Merck and Co of the United States, despite near-identical names and similar share prices.
- Merck KGaA agreed to buy UK biotech Silence Therapeutics for about $1.1 billion in cash, paying $20 per American depositary share, a 130% premium to Friday’s close. Silence more than doubled to as high as $19.61 while Merck fell as much as 1.7%.
- That premium implies the public market valued Silence at under half what a strategic buyer would pay, days after positive results for divesiran in a rare, slow-growing blood cancer. Bloomberg Intelligence cites analyst consensus of about $400 million in annual sales by the mid-2030s if the drug launches in 2030, so Merck is paying roughly 2.75 times eventual peak sales for an unapproved medicine a decade ahead of that peak.
- Chief executive Kai Beckmann has moved quickly. This is his second takeover since taking over earlier this year, following the $11.3 billion purchase of Bio-Techne in June, the company’s largest deal in more than a decade. Both are funded with new debt, totalling $12.4 billion of commitments in roughly four months.
- The motivation is pipeline pressure. Merck is strengthening its drug portfolio after development setbacks while its multiple sclerosis treatment Mavenclad faces increasing generic competition, building on the SpringWorks Therapeutics purchase last year.
What Happened?
Silence chairman Iain Ross said divesiran has the potential to be a best-in-class therapy. The $1.1 billion figure reflects enterprise value and the transaction is expected to close next quarter.
Why It Matters?
The premium is the most informative number and it describes the state of small-cap biotech generally rather than this company specifically. Public investors were valuing Silence at roughly $478 million immediately after favourable clinical data, and a pharmaceutical company with a pipeline gap paid more than twice that within days. The same discount is visible elsewhere: Iambic Therapeutics listed at $758 million having raised $461.8 million privately over seven years, and Disc Medicine rose 55% this morning on a single Phase 3 result. Development-stage biotech is cheap because public markets will not fund it patiently, which makes it a buyer’s market for large pharmaceutical companies with revenue to replace. For investors the read is that acquisition premiums in this sector are likely to stay wide while the funding gap persists. The pace and funding of Merck’s dealmaking is the question for its own shareholders. A chief executive less than a year into the role has committed $12.4 billion across two acquisitions, both financed with new debt, while the existing business faces generic erosion. Each asset may be sensible and the combination raises ordinary questions about leverage and integration capacity, particularly as the debt is being raised in a market where high-grade issuers have been standing aside and Kimberly-Clark is being forced to price a deal its peers are avoiding. Buying pipeline when your own development disappoints is standard practice, and it is also the moment when sellers have the most leverage. On the asset itself, 2.75 times projected peak sales is within normal pharmaceutical ranges, and the risk sits in the gap between an encouraging trial result and a launch that is four years away in a rare indication.
What Next?
Completion is expected next quarter and the debt raised to fund it will show the cost of the financing. Watch divesiran’s regulatory pathway, since a 2030 launch assumption underpins the valuation and rare disease approvals can move in either direction. For Merck, integrating Bio-Techne and Silence simultaneously is the operational test, and Mavenclad’s generic erosion is the pressure driving the strategy. For the sector, whether other large pharmaceutical companies pay comparable premiums will show if this is a repricing of small-cap biotech or a single competitive situation.
Affected Tickers and Coins: MRK, SLN, TECH
Source: Bloomberg
